Zhejiang Dayang Biotech Group Co Ltd

Zhejiang Dayang Biotech Group Co Ltd maintains a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure with total liabilities of CNY 601.4 million and total equity of CNY 1.05 billion. The company's liquidity position is characterized by a current ratio of 1.22, suggesting moderate short-term liquidity, though its cash and equivalents of CNY 2.75 million are significantly lower than its long-term debt of CNY 369.8 million. Profitability metrics show a return on equity (ROE) of 6.07% and a return on assets (ROA) of 3.86%, which are below the typical thresholds for high-margin chemical producers. The company's net income of CNY 63.9 million on revenue of CNY 909.96 million reflects a net margin of 7.03%, which is in line with the lower end of the commodity chemicals industry's profitability range. The company's revenue is derived from a mix of domestic and international markets, though the exact geographic breakdown is not disclosed. Its product portfolio includes potassium carbonate, potassium bicarbonate, and veterinary raw materials, with no single customer or product accounting for a dominant share of revenue. Looking ahead, the company's revenue is projected to grow at a modest pace, with the current fiscal year (FY) and next FY outlooks showing a directional increase, though the exact numeric deltas are not disclosed. The company's capital expenditure of CNY -63.45 million indicates a reduction in investment, which may reflect a strategic shift or cost containment. Risk factors include a medium liquidity risk due to the current ratio of 1.22 and a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no immediate pressure from share issuance or dilution events. Recent filings and transcripts do not indicate any material events or strategic shifts, though the company's financial performance and capital structure suggest a focus on maintaining operational stability over aggressive expansion.